- Sagimet Bio, a clinical-stage biopharmaceutical company, is advancing its fatty acid synthase (FASN) inhibition programs for NASH and acne.  **[1400118_tx_379750_0]** 
- In NASH, a Phase I PK study of its lead molecule, **denifanstat**, combined with **resmetirom** in F4 cirrhotic patients is starting, with data anticipated by the end of **2025** or early **2026**.  **[1400118_tx_379750_0]**  The company holds IP on this combination until **2044**.  **[1400118_tx_379750_5]** 
- For acne, Sagimet's partner Ascletis reported positive Phase III results for **denifanstat** in China, showing statistically significant results across all primary and secondary endpoints and a good safety profile.  **[1400118_tx_379750_1]**  Sagimet is progressing its next-generation molecule, **3,567**, into a Phase I study, with completion expected by early **2026** and a Phase II program planned for the first half of **2026**.  **[1400118_tx_379750_0]**  The IP for **3,567** extends to **2046**.  **[1400118_tx_379750_1]** 
- Sagimet has approximately **$135 million** in cash, providing a financial runway until **2028**, which is expected to cover the Phase IIb biopsy study for NASH and the continued development of **3,567** in acne.  **[1400118_tx_379750_6]**

Sagimet Biosciences (SGMT)